Imfinzi (durvalumab) vs Lorviqua (lorlatinib)
Imfinzi (durvalumab) vs Lorviqua (lorlatinib)
Imfinzi (durvalumab) is an immune checkpoint inhibitor specifically designed to target the PD-L1 protein, and is primarily used in the treatment of certain types of lung cancer and bladder cancer. Lorviqua (lorlatinib) is a targeted therapy known as an ALK and ROS1 inhibitor, used to treat non-small cell lung cancer (NSCLC) in patients whose tumors have specific genetic mutations. When deciding between Imfinzi and Lorviqua, it is crucial to consider the specific type of cancer, its molecular profile, and the presence of particular genetic markers, as these factors will determine which medication is more appropriate for the individual's condition.
Difference between Imfinzi and Lorviqua
| Metric | Imfinzi (durvalumab) | Lorviqua (lorlatinib) |
|---|---|---|
| Generic name | Durvalumab | Lorlatinib |
| Indications | Urothelial carcinoma, non-small cell lung cancer | Non-small cell lung cancer |
| Mechanism of action | PD-L1 inhibitor | ALK and ROS1 inhibitor |
| Brand names | Imfinzi | Lorviqua |
| Administrative route | Intravenous | Oral |
| Side effects | Fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral edema, urinary tract infection | Hypercholesterolemia, hypertriglyceridemia, edema, peripheral neuropathy, cognitive effects, mood effects |
| Contraindications | Hypersensitivity to durvalumab or any excipients | Hypersensitivity to lorlatinib or any excipients |
| Drug class | PD-L1 blocking antibody | ALK and ROS1 tyrosine kinase inhibitor |
| Manufacturer | AstraZeneca | Pfizer |
Efficacy
Imfinzi (Durvalumab) Efficacy in Lung Cancer
Imfinzi (durvalumab) is an immune checkpoint inhibitor specifically targeting the PD-L1 protein, which is used in the treatment of lung cancer. Its efficacy has been particularly noted in non-small cell lung cancer (NSCLC). Clinical trials have demonstrated that durvalumab can significantly improve progression-free survival (PFS) in patients with locally advanced, unresectable NSCLC who have not progressed following concurrent platinum-based chemotherapy and radiation therapy. The PACIFIC trial, a pivotal study for durvalumab, showed a substantial increase in median PFS and overall survival (OS) when compared to placebo, establishing durvalumab as a standard treatment option in this setting.
Furthermore, durvalumab has been evaluated in other stages of NSCLC and has shown promise in improving outcomes when used as part of first-line therapy in combination with other agents. Its role in extensive-stage small cell lung cancer (SCLC) is also being explored, with research indicating potential benefits in combination with standard chemotherapy. However, the primary focus and approval for durvalumab remain in the treatment of stage III NSCLC following chemoradiation.
Lorviqua (Lorlatinib) Efficacy in Lung Cancer
Lorviqua (lorlatinib) is a third-generation anaplastic lymphoma kinase (ALK) inhibitor used in the treatment of ALK-positive NSCLC. It is designed to target ALK mutations that drive the growth of cancer cells. Lorlatinib has shown high efficacy in patients with ALK-positive metastatic NSCLC who have progressed on prior ALK inhibitors. The drug has demonstrated a robust intracranial response in patients with brain metastases, a common complication of ALK-positive NSCLC, which is a significant advantage over earlier-generation ALK inhibitors.
In clinical trials, lorlatinib has shown impressive overall response rates (ORR) and appears to be effective in patients who have become resistant to prior ALK-targeted therapies. Its efficacy in treatment-naive ALK-positive NSCLC patients is also being investigated, with early data suggesting a strong potential as a first-line treatment. Lorlatinib's ability to overcome various ALK mutations makes it a valuable treatment option for patients with ALK-positive NSCLC, particularly those with advanced disease and CNS involvement.
Regulatory Agency Approvals
Imfinzi
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Lorviqua
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
Access Imfinzi or Lorviqua today
If Imfinzi or Lorviqua are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us